A key panel of directors of the California stem cell agency on Tuesday will wrestle with ongoing issues involving its critical grants management system and consider changes in its policies concerning the many outside contractors CIRM is forced to rely on.
The agency has already posted some background information for the Governance Subcommittee meeting including a list of current contracts and